A case of planned pregnancy with an interruption in infliximab administration in a 27-year-old female patient with rheumatoid-factor-positive polyarthritis juvenile idiopathic arthritis which improved after restarting infliximab and methotrexate.
We report a 27-year-old case of juvenile idiopathic arthritis (JIA) having been stopped infliximab during pregnancy. She was safely treated by infliximab therapy with premedications for preventing infusin reactions after her delivery, and then improved in the same manner as when she had been treated with infliximab therapy before pregnancy. As a result, it remains unclear whether or not we can use infliximab to control disease activities during pregnancy. In addition, it is also important to clarify whether or not premedications should be used when resuming infliximab treatment in such patients after pregnancy. These problems still remain controversial. More definitive data are needed in order to allow rheumatologists to better select the optimal TNF-alpha inhibitor therapy when treating pregnant JIA patients.
Nerome
Yasuhito
Y
Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. nerome@m.kufm.kagoshima-u.ac.jp
Imanaka
Hiroyuki
H
Nonaka
Yukiko
Y
Tsuru
Yumiko
Y
Maeno
Nobuaki
N
Takezaki
Tomoko
T
Mori
Hirosumi
H
Akaike
Harumi
H
Kubota
Tomohiro
T
Kawano
Yoshifumi
Y
Takei
Syuji
S
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy* / Q000503:physiopathology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005193:Family Planning Services; D005260:Female; D006801:Humans; D000069285:Infliximab; D007275:Injections, Intravenous; D050498:Live Birth; D008727:Methotrexate / Q000627:therapeutic use*; D011247:Pregnancy; D011248:Pregnancy Complications; D012720:Severity of Illness Index; D028761:Withholding Treatment
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab; D008727:Methotrexate